Exploristics collaborate with Newcastle University Biostatistics Research Group

Exploristics collaborate with Newcastle University Biostatistics Research Group

Exploristics collaborate with Newcastle University Biostatistics Research Group 554 276 Exploristics

Exploristics is pleased to announce a new collaboration with the Biostatistics Research Group at the Population Health Sciences Institute at Newcastle University to investigate the use of artificial intelligence (AI)/machine learning (ML) approaches in the generation of external control arms for clinical trials. Newcastle University researcher Nicole Cizauskas will be leveraging the powerful synthetic data generation capabilities of Exploristics’ innovative simulation software, KerusCloud, to create highly realistic correlated patient-level data with known characteristics for use in an investigation of different AI/ML modelling approaches.

Sam Miller, Head of Strategic Consulting at Exploristics said, “Ground-breaking research and innovation are at the heart of the technology-enabled services we provide and so we are very pleased to collaborate on this exciting new project. KerusCloud is an incredibly versatile and powerful cloud computing platform that can rapidly generate highly realistic synthetic datasets for a myriad of analytics applications. This offers a validated approach to mimicking the characteristics of correlated subject-level data to enable valuable research that might otherwise be restricted by limited access to data, for example due to rare diseases or privacy issues. We are delighted that Nicole will be able to utilise KerusCloud for these purposes.”

Nicole Cizauskas, Researcher in the Biostatistics Research Group, Newcastle University added, “The KerusCloud software allows the generation of synthetic data to be expedited while maintaining high data quality; this is particularly useful for AI and machine learning modelling which requires large amounts of training and testing data.  In my research, I will use a generative model to create synthetic control arms based on previous trial data for uses in rare diseases.  The rapid generation of synthetic data with KerusCloud permits these methods to be built better, faster, and include more diverse targets of interest.  In addition to this, the support from the Exploristics team has given a unique industry perspective to my research, allowing me to focus on wider accessibility of the final product.”

About the Biostatistics Research Group, Newcastle University

The Population Health Sciences Institute Biostatistics Research Group (PHSI-BRG) at Newcastle University consists of 33 statistics who work to develop and implement innovative methods for medical research studies. PHSI-BRG has particular expertise in methods for innovative trial design (adaptive designs, master protocols) and using external information to augment trials (external/synthetic controls, Bayesian borrowing). It provides statistical expertise to a large portfolio of clinical trials and observational studies, working closely with Newcastle Clinical Trials Unit and the NIHR Research Design Service North East and North Cumbria.

About Exploristics

Exploristics is a world-leading technology-enabled services company that transforms clinical development for life sciences organisations with unique proprietary software and biostatistics consultancy supporting the planning, design, and analysis of clinical studies. For more information on Exploristics please visit www.exploristics.com or follow us on LinkedIn or X (Formerly Twitter).

About KerusCloud

KerusCloud is a revolutionary simulation-guided study design tool that ensures clinical trials are designed effectively to collect the right data, in the right patients, in the right way. Its use supports evidence-based design decisions to extensively de-risk real clinical studies, reducing development times, costs, and patient burden.

For more information on KerusCloud and its use as a synthetic data generator please visit https://exploristics.com/synthetic-dataset-generation/

Learn how KerusCloud helped raise US$30 million in a subsequent financing round

X